MUMBAI, India, July 11 -- Intellectual Property India has published a patent application (202541060214 A) filed by Saveetha Institute Of Medical And Technical Sciences, Chennai, Tamil Nadu, on June 24, for 'development of biodegradable gel with dual action:anti-cancer and wound healing for postsurgical oral squamous cell carcinoma patients.'
Inventor(s) include Dr. Selvaraj Jayaraman; Dr. Vishnu Priya Veeraraghavan; and Dr. Deepak Nallaswamy Veeraiyan.
The application for the patent was published on July 11, under issue no. 28/2025.
According to the abstract released by the Intellectual Property India: "Oral squamous cell carcinoma (OSCC) is a highly prevalent and aggressive malignancy of the oral cavity. Surgical resection remains a primary treatment, often followed by chemotherapy or radiotherapy. However, post-surgical complications including infection, delayed wound healing, and high recurrence rates continue to challenge effective long-term outcomes. Conventional therapies do not adequately address both residual cancer cell elimination and tissue regeneration. Therefore, an urgent need exists for localized, dual-functional therapeutics to improve postoperative care in OSCC patients. To develop and evaluate a biodegradable gel formulation that combines natural bioactive compounds (Aloe vera and honey) with a standard chemotherapeutic ------=a,gent (s:i'fuoro.unicl~ fordua(ac-tion .. targetlng.residua[cancer.ceiis.ancLpromotingwouna healing in post-surgical OSCC patients. A biodegradable gel matrix was developed incorporating Aloe vera extract, honey, and 5-tluorouracil (5-FU). The gel was optimized for bio-adhesiveness, degradation rate, and controlled release kinetics. In vitro assessments were conducted using human oral cancer cell lines (e.g., SCC-9 or HSC-3) to evaluate cytotoxic effects of the gel against cancer cells. Concurrently, wound-healing assays using fibroblast and epithelial cell lines were performed to assess regenerative potential. Antimicrobial activity was evaluated against common oral pathogens. Controlled release studies and biocompatibility assessments were also performed. The gel demonstrated sustained release of 5-FU and bioactive compounds over 72 hours. In vitro cytotoxicity assays showed significant inhibition of oral cancer cell proliferation (p < 0.05), while wound-healing assays revealed enhanced cell migration and tissue regeneration compared to control groups. The inclusion of Aloe vera and honey improved anti-inflammatory and antimicrobial properties, further supporting post-surgical application. The gel exhibited excellent biocompatibility and biodegradability without inducing cytotoxic effects on normal oral mucosal cells. The developed biodegradable gel offers a novel dual-action platform for post-surgical OSCC therapy by integrating anti-cancer and wound-healing functionalities. This localized drug delivery system has the potential to reduce recurrence, improve healing outcomes, and minimize systemic side effects, presenting a significant advancement in oral cancer post-operative care."
Disclaimer: Curated by HT Syndication.
